Pettengell Ruth, Silvestre Antonio Salar, Schwenkglenks Matthias, Rossi Francesca Gaia, Duehrsen Ulrich, Verhoef Gregor, Lugtenburg Pieternella Johanna, Wheeler Tracey, Pujol Beatriz, Haioun Corinne
Haematology, St George's University of London, London SW17 0RE, UK.
Hematology. 2013 Jan;18(1):26-9. doi: 10.1179/1607845412Y.0000000033. Epub 2012 Sep 12.
IMPACT NHL was a multicenter, observational study in adults with non-Hodgkin lymphoma receiving CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy with or without rituximab. Erythropoietin-stimulating agent treatment was given according to routine clinical practice and physician preference. In a subanalysis, outcomes were evaluated in 207 patients who received darbepoetin alfa (DA). The most common reason (81%) for initiating DA was low/declining hemoglobin (Hb) concentration. Mean (±standard deviation) duration of DA exposure was 8.8 ± 6.9 weeks (mean number of doses, 5.1 ± 4.6). Overall, 23% of patients had chemotherapy and DA treatment synchronized more than 75% of the time. At the time of DA initiation, 67% of patients had Hb concentrations in the guideline-recommended range (9-11 g/dl). Of 89 patients with Hb concentrations <10 g/dl at DA initiation and still receiving DA 5 weeks later, 92% (Kaplan-Meier) achieved Hb concentrations 10-12 g/dl between week 5 and at the end of treatment.
IMPACT NHL是一项针对接受CHOP（环磷酰胺、阿霉素、长春新碱和泼尼松龙）化疗（联合或不联合利妥昔单抗）的非霍奇金淋巴瘤成人患者的多中心观察性研究。促红细胞生成素治疗根据常规临床实践和医生偏好进行。在一项亚分析中，对207例接受达贝泊汀α（DA）治疗的患者的结局进行了评估。开始使用DA的最常见原因（81%）是血红蛋白（Hb）浓度低/下降。DA暴露的平均（±标准差）持续时间为8.8±6.9周（平均给药次数，5.1±4.6）。总体而言，23%的患者化疗和DA治疗同步时间超过75%。在开始使用DA时，67%的患者Hb浓度在指南推荐范围内（9-11 g/dl）。在开始使用DA时Hb浓度<10 g/dl且在5周后仍接受DA治疗的89例患者中，92%（Kaplan-Meier法）在第5周和治疗结束时Hb浓度达到10-12 g/dl。
